Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium breve SHMB 8001
- Development stage
- Preclinical
- Lead developer
- Shanghai Children’s Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve SHMB 8001 is a novel probiotic strain isolated from human milk, currently being investigated as a live biotherapeutic for the treatment of inflammatory bowel disease (IBD). In preclinical studies using DSS-induced colitis mouse models, the strain demonstrated significant anti-inflammatory properties. Its mechanism of action involves the restoration of intestinal barrier integrity by upregulating tight junction proteins, specifically occludin and claudin-1, and the modulation of the gut microbiota community. Furthermore, SHMB 8001 administration leads to a reduction in the levels of key proinflammatory cytokines, including TNF-α, IL-1β, and IL-6. The development is being led by researchers at Shanghai Children’s Hospital and Shanghai Jiao Tong University.
- Other names
- B. breve SHMB 8001
02
Targets
IL-6 (Interleukin 6)IL10 (Interleukin-10)CLDN1 (Tight junction protein claudin-1)TNFA (Tumor necrosis factor alpha (soluble))OCLN (Occludin)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Bifidobacterium breve SHMB 8001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium breve SHMB 8001.